Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label Study on the Efficacy, Tolerability, and Total Costs of Olanzapine Versus Conventional Antipsychotics in the Treatment of Acute Mania in Sweden

NCT00767715 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00767715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00767715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label Study on the Efficacy, Tolerability, and Total Costs of Olanzapine Versus Conventional Antipsychotics in the Treatment of Acute Mania in Sweden
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Terminated
Start date
October 31, 2004
Completion date
April 30, 2005
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder